Open Access Full Text Article

ORIGINAL RESEARCH

Relationship Between Systemic Immune-Inflammation Index and Risk of Respiratory Failure and Death in COPD: A Retrospective Cohort Study Based on the MIMIC-IV Database

Ye Zhang¹, Xiaoli Tan², Shiyu Hu³, Zhifang Cui⁴, Wenyu Chen²

¹Department of General Medicine, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China; ²Department of Respiratory Medicine, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China; ³Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Jiaxing, Zhejiang, People's Republic of China; ⁴Department of Respiratory Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China

Correspondence: Wenyu Chen, Department of Respiratory Medicine, Affiliated Hospital of Jiaxing University, No. 1882, Zhonghuan South Road, Nanhu District, Jiaxing City, Zhejiang Province, 314001, People's Republic of China, Email 00135116@zjxu.edu.cn

Purpose: Chronic obstructive pulmonary disease (COPD) concurrent with respiratory failure (RF) is devastating, and may result in death and disability. Systemic immune-inflammation index (SII) is a new prognostic biomarker linked to unfavorable outcomes of acute coronary syndrome, ischemic stroke, and heart failure. Nonetheless, its role in COPD is rarely investigated. Consequently, this study intends to assess the accuracy of SII in predicting the prognosis of COPD.

Patients and Methods: The clinical information was retrospectively acquired from the Medical Information Mart for Intensive Care-IV database. The outcomes encompassed the incidence of RF and mortality. The relationship between different SII and outcomes was examined utilizing the Cox proportional-hazards model and restricted cubic splines. Kaplan-Meier analysis was employed for all-cause mortality.

Results: The present study incorporated 1653 patients. During hospitalization, 697 patients (42.2%) developed RF, and 169 patients (10.2%) died. And 637 patients (38.5%) died during long-term follow-up. Higher SII increased the risk of RF (RF: HR: 1.19, 95% CI 1.12–1.28, P<0.001), in-hospital mortality (HR: 1.22, 95% CI 1.07–1.39, P=0.003), and long-term follow-up mortality (HR: 1.12, 95% CI 1.05–1.19, P<0.001). Kaplan-Meier analysis suggested a significantly elevated risk of all-cause death (log-rank P<0.001) in patients with higher SII, especially during the short-term follow-up period of 21 days.

Conclusion: SII is closely linked to an elevated risk of RF and death in COPD patients. It appears to be a potential predictor of the prognosis of COPD patients, which is helpful for the risk stratification of this population. However, more prospective studies are warranted to consolidate our conclusion.

Keywords: systemic immune-inflammation index, chronic obstructive pulmonary disease, respiratory failure, mortality, MIMIC-IV database

Introduction

Chronic obstructive pulmonary disease (COPD) is a prevalent long-lasting airway inflammatory condition that features enduring respiratory symptoms and irreversible airflow restriction.^{1,2} Globally, COPD ranks third in terms of cause of death behind ischemic heart disease and cerebrovascular disease, owing to high morbidity and mortality rates.^{3,4} Respiratory failure (RF), especially hypercapnic RF (HRF), frequently occurs in most COPD patients at severe or end-stage.^{5,6} COPD complicated by RF (COPD+RF) increases the difficulty of treatment, resulting in poor prognosis.⁷ COPD+RF patients usually require unplanned hospitalization or intensive care unit (ICU). The short-term mortality reaches nearly 30%,^{8–10} and the mortality of critically ill patients who need mechanical ventilation is as high as 50%.^{11,12}

This undoubtedly has a huge negative influence on patients' health, economy, and quality of life. Therefore, early identification of the risk of RF in COPD patients is of significant importance. Exploring an easily accessible biomarker related to the incidence of RF to predict the clinical outcome can assist clinicians in determining high-risk patients early and implementing preventative strategies.

Despite the elusive pathogenesis of RF in COPD, aberrant immune activation and systemic inflammation constitute key contributors.^{13,14} The systemic immune-inflammation index (SII) is a comprehensive inflammatory indicator that is computed by peripheral lymphocyte, neutrophil, and platelet counts. Neutrophils, platelets, and produced cytokines are mostly tied to nonspecific immune responses.^{14–17} In contrast, lymphocytes are primarily linked to immune-related pathways.^{14–17} SII is more stable and can more accurately reflect the inflammation state of the human body than the absolute count of a single immune cell.^{18,19} In addition, due to low costs and easy accessibility, it is regarded as a powerful inflammatory indicator of both local immune response and systemic inflammation.^{20,21} In recent years, SII has been demonstrated to be indicative of poor prognosis of cardiovascular diseases,^{22,23} stroke,^{24,25} acute kidney injury²⁶ and sepsis.²⁷ However, no study, particularly with large sample sizes, has been done to discern how SII influences the prognosis of critically ill COPD patients.

Therefore, the current study intends to probe into the relationship between SII and the risk of RF and death in critically ill patients with COPD and to assess the prognostic value of SII in this population, providing guidance for the prevention and treatment of COPD+RF.

Materials and Methods

Data Sources

Relevant data were retrospectively acquired from the Medical Information Mart for Intensive Care-IV (MIMIC-IV version 2.2) database (https://physionet.org/content/mimiciv/2.2/). MIMIC-IV is a sizable and openly accessible database established and operated by the Massachusetts Institute of Technology (MIT). It includes the clinical data of 299,712 patients hospitalized in the Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. We have completed the courses required to use this database and obtained access to the database (authentication No.: 52663507). All the protected private information of patients has been de-identified. Ethical approval for this study was obtained from the Medical Research Ethics Committee of The First Hospital of Jiaxing (No. 2023-LY-633).

Study Population

Data on all patients were obtained from the MIMIC-IV database. The following patients were incorporated into our analysis: (1) Patients who were diagnosed with COPD according to the ninth and tenth revisions of the International Classification of Diseases (ICD-9 codes: 491.20, 491.21, 491.22 and 496; ICD-10 codes: J 44, J 44.0, J 44.1 and J 44.9); (2) patients who aged 18 and above. The following patients were excluded: (1) Patients who were hospitalized for less than 24 hours; (2) patients who had RF at admission; (3) patients whose platelet, neutrophil, and lymphocyte counts were missing or zero.

Data Extraction and Integration

PostgreSQL tool (version 14.6, <u>https://www.postgresql.org/</u>) was leveraged to extract patient data at their first admission from the MIMIC-IV database, encompassing demographic data (age, gender, race, BMI), vital signs (heart rate, blood pressure, respiratory rate, etc.), complications (hypertension, diabetes, atrial fibrillation, asthma, cancer, etc.), laboratory tests (blood routine, biochemical indicators, blood gas analysis, etc.), disease severity score [sequential organ failure assessment (SOFA), acute physiology score III (APSIII), simplified acute physiology score II (SAPSII), etc.], and treatment measures (glucocorticoid, bronchodilator, antibiotics, mechanical ventilation, etc.).

SII was computed utilizing the formula: SII = platelet count \times neutrophil count/lymphocyte count.²⁰ We extracted data on patients at their first admission. For indicators that were measured multiple times, we only used the results at the first measurement. For vital signs, laboratory tests, treatment measures, and other data, we only analyzed the data before patients developed RF.

Primary Outcome and Secondary Outcomes

The primary outcome was the incidence of RF. According to the Guidelines for Chronic Obstructive Pulmonary Disease,²⁸ RF was defined as arterial oxygen partial pressure (PaO2) < 60 mmHg or PaO2/fractions of inspired oxygen (FiO2) \leq 300 mmHg, with or without carbon dioxide (CO2) retention. Among them, carbon dioxide retention (PaCO2>50mmHg) means HRF.

Secondary outcomes consisted of in-hospital all-cause mortality and mortality during long-term follow-up. In-hospital mortality encompassed ICU death and general ward inpatient death. The information on the mortality of discharged patients was derived from the United States Social Security Death Index.

Missing Data

The variables that had more than 20% missing values were categorized based on the database's reference range and converted into dummy variables for analysis. For variables with less than 20% missing values, the random-forest multiple imputation method was utilized to estimate the missing values.²⁹

Statistical Analysis

According to the quartile of SII index, all patients were randomized into four groups. Normally distributed continuous variables were reported using mean \pm standard deviation (SD), while abnormally distributed continuous variables were displayed as median and interquartile range [M (Q1, Q3)]. Categorical variables were reported as number and percentage (%). Comparisons of continuous variables were conducted utilizing the *t*-test or non-parametric test, and Pearson's chi-square test or Fisher's exact test was leveraged for categorical variable comparisons. To guarantee the comparability of baseline features across groups, covariates were adjusted utilizing Propensity score matching (PSM). The baseline traits of the original queue and the matching queue were displayed, separately.

The relationship between SII and the risk of outcomes was discerned employing the Cox proportional-hazards models, with hazard ratio (HR) with 95% confidence interval (CI) as the effect size. Three multivariate models were established based on the quartile of SII. No variables were adjusted in Model 1. Age and gender were adjusted in Model 2. On the basis of model 2, Model 3 was further adjusted for other 24 variables, encompassing asthma, acute myocardial infarction (AMI), atrial fibrillation (AF), cerebrovascular disease, chronic kidney disease (CKD), hypertension, heart failure(HF), liver disease, pneumonia, sepsis, acute exacerbations of chronic obstructive pulmonary disease (AECOPD), smoke, bronchodilator, glucocorticoid, mechanical ventilation, albumin, red cell distribution width (RDW), triglycerides, c-reactive protein, tidal volume, vital capacity, APSIII, SOFA and hemoglobin. Restricted cubic splines (RCS) model was adopted to delve into the nonlinear relationship between SII and the risk of RF and death in COPD patients. The Kaplan-Meier survival curve was leveraged to examine the relationship between different SII indexes and mortality, and the differences between groups were evaluated by Log rank test. Because of the non-normal distribution of SII, SII was converted into a logarithmic scale to minimize the skewness of the basic distribution.

Subgroup analysis was carried out to determine whether the relationship between SII and primary outcome indicators was consistent in different subgroups, and that SII was stable as a prognostic marker, such as age (≤ 65 years old and > 65 years old), gender, body mass index (BMI) (≤ 30 and > 30 kg/m2), and presence of hypertension, diabetes, coronary heart disease, cancer, dyslipidemia, heart failure, ischemic heart disease, liver disease, AECOPD, smoke, pneumonia and sepsis. Statistical analysis was executed utilizing the R software (version 4.2.3; R foundation for statistical computing, Vienna). P < 0.05 indicates a statistical difference.

Results

14,050 individuals with COPD were retrospectively extracted from the MIMIC-IV 2.2 database. Finally, 1653 COPD patients were analyzed in our study (Figure 1), encompassing 879 (53.2%) males and 774 (46.8%) females, and most of them were white people. The average age was 71.00 years (range 62.00–78.00 years). The average SII was 1302.17 (range 634.51–2821.88). RF occurred in 697 patients (42.2%), and HRF occurred in 427 patients (25.8%). Additionally, 169 patients (10.2%) died in hospital, with 39 deaths (2.3%) during hospitalization and 130 cases (7.9%) in ICU. During




Figure I Flow chart of patient screening.

Abbreviations: MIMIC-IV, Medical Information Mart for Intensive Care-IV; n, Number; COPD, chronic obstructive pulmonary disease.

the follow-up, 637 patients (38.5%) died. The median follow-up time for RF, in-hospital death and follow-up death were 5.00 [1.00, 9.00], 8.00 [5.00, 15.00] and 29.00 [8.00, 187.00] days, respectively.

Baseline Characteristics

The baseline features of SII groups are delineated in Table 1. Patients in the high SII group were mostly old, white, and males, with more unstable vital signs and higher disease scores at admission compared to the low SII group. Individuals with higher SII had a higher incidence of developing cancers, heart failure, AECOPD, pneumonia, and sepsis, but they were less likely to suffer from liver diseases and dyslipidemia. Their white blood cells, neutrophils, platelets, RDW, serum phosphorus, serum urea nitrogen, partial pressure of carbon dioxide and serum glucose levels were also higher, while the levels of red blood cells, hemoglobin, lymphocyte count, albumin, PH, PaO2, sodium ion, and chloride were lower. In addition, patients with high SII were also most likely to use glucocorticoids, antibiotics, vasopressors, oxygen, and invasive ventilation.

With the rise in SII index, ICU stay (1.05 days vs 1.36 days vs 1.68 days vs 2.45 days, P <0.001), hospitalization time (7.00 days vs 8.00 days vs 9.00 days, P <0.001), RF rate (28.3% vs 38.7% vs 42.6% vs 59.1% P<0.001), the incidence of HRF (16.4% vs 23.5% vs 27.1% vs 36.3%, P<0.001), ICU mortality (4.6% vs 6.3% vs 8.0% vs 12.6%, P<0.001), and in-hospital mortality (6.0% vs 7.3% vs 11.6% vs 16.0%, P<0.001) and long-term follow-up mortality

Table I The Baseline Clinical Characteristics of the Study Population

characteristics	SII						
		QI	Q1 Q2		Q4		
	Total	SII≥634.5 I	634.5 I <sii≤i 302.="" 7<="" i="" th=""><th>I302.I7<sii≤2821.88< th=""><th>SII>2821.88</th><th></th></sii≤2821.88<></th></sii≤i>	I302.I7 <sii≤2821.88< th=""><th>SII>2821.88</th><th></th></sii≤2821.88<>	SII>2821.88		
Participants, N	1653	414	413	413	413		
Demographics							
Age, years	71.00 [62.00, 78.00]	67.00 [58.00, 75.00]	71.00 [63.00, 79.00]	71.00 [62.00, 79.00]	73.00 [65.00, 79.00]	<0.001	
Gender, n (%)							
Male	879 (53.2)	240 (58.0)	216 (52.3)	212 (51.3)	211 (51.1)	0.155	
Female	774 (46.8)	174 (42.0)	197 (47.7)	201 (48.7)	202 (48.9)		
Race, n (%)						0.044	
White	1190 (72.0)	300 (72.5)	299 (72.4)	309 (74.8)	282 (68.3)		
Black	56 (3.4)	19 (4.6)	19 (4.6)	7 (1.7)	11 (2.7)		
Asian	27 (1.6)	10 (2.4)	7 (1.7)	5 (1.2)	5 (1.2)		
Other	380 (23.0)	85 (20.5)	88 (21.3)	92 (22.3)	115 (27.8)		
Vital signs							
HR, beats/min	86.00 [77.00, 99.00]	82.00 [75.00, 93.00]	83.00 [76.00, 95.00]	87.00 [77.00, 103.00]	91.00 [80.00, 104.00]	<0.001	
RR, breaths/min	18.00 [16.00, 22.00]	17.00 [15.00, 20.00]	17.00 [15.00, 20.00]	20.00 [16.00, 22.00]	20.00 [16.00, 24.00]	<0.001	
MBP, mmHg	79.50 [69.75, 93.00]	79.00 [69.00, 90.75]	78.00 [68.00, 92.00]	81.00 [71.00, 94.00]	80.00 [71.00, 93.00]	0.123	
Spo2, %	97.00 [94.00, 100.00]	99.00 [95.00, 100.00]	97.00 [95.00, 100.00]	97.00 [94.00, 100.00]	96.00 [92.00, 99.00]	<0.001	
Temperature, °C	36.78 [36.44, 37.06]	36.67 [36.39, 37.00]	36.78 [36.40, 37.00]	36.78 [36.56, 37.11]	36.78 [36.47, 37.06]	0.005	
BMI, kg/m ²	27.40 [23.40, 32.80]	27.70 [23.60, 32.80]	28.00 [23.60, 32.52]	27.20 [23.05, 33.40]	26.50 [22.67, 31.55]	0.178	
Comorbidities, n (%)							
Hypertension	1175 (71.1)	295 (71.3)	292 (70.7)	287 (69.5)	301 (72.9)	0.754	
DM	523 (31.6)	136 (32.9)	130 (31.5)	139 (33.7)	118 (28.6)	0.414	
Asthma	145 (8.8)	41 (9.9)	37 (9.0)	37 (9.0)	30 (7.3)	0.599	
HF	639 (38.7)	127 (30.7)	178 (43.1)	163 (39.5)	171 (41.4)	0.001	
CHD	601 (36.4)	154 (37.2)	156 (37.8)	172 (41.6)	119 (28.8)	0.001	
AMI	235 (14.2)	50 (12.1)	57 (13.8)	72 (17.4)	56 (13.6)	0.154	
AF	285 (17.2)	55 (13.3)	76 (18.4)	75 (18.2)	79 (19.1)	0.102	
IHD	702 (42.5)	178 (43.0)	178 (43.1)	201 (48.7)	145 (35.1)	0.001	
Cancer	411 (24.9)	96 (23.2)	82 (19.9)	100 (24.2)	133 (32.2)	<0.001	
Cerebrovascular disease	195 (11.8)	59 (14.3)	43 (10.4)	49 (11.9)	44 (10.7)	0.298	
CKD	396 (24.0)	96 (23.2)	85 (20.6)	105 (25.4)	110 (26.6)	0.185	
Liver disease	237 (14.3)	83 (20.0)	59 (14.3)	47 (11.4)	48 (11.6)	0.001	
Dyslipidemia	828 (50.1)	218 (52.7)	219 (53.0)	212 (51.3)	179 (43.3)	0.016	
Pneumonia	361 (21.8)	59 (14.3)	77 (18.6)	90 (21.8)	135 (32.7)	< 0.001	

463

(Continued)

Zhang et al

characteristics	SII						
	QI		Q2	Q3	Q4	-	
	Total	SII≥634.5 I	634.5I <sii≤i302.i7< th=""><th> 302. 7<sii≤282 .88< th=""><th>SII>2821.88</th><th></th></sii≤282 .88<></th></sii≤i302.i7<>	302. 7 <sii≤282 .88< th=""><th>SII>2821.88</th><th></th></sii≤282 .88<>	SII>2821.88		
Bacterial pneumonia	87 (5.3)	16 (3.9)	18 (4.4)	21 (5.1)	32 (7.7)	0.059	
Viral pneumonia	8 (0.5)	0 (0.0)	I (0.2)	3 (0.7)	4 (1.0)	0.169	
Ventilator associated pneumonia	64 (3.9)	10 (2.4)	9 (2.2)	18 (4.4)	27 (6.5)	0.003	
Sepsis	294 (17.8)	43 (10.4)	53 (12.8)	66 (16.0)	132 (32.0)	<0.001	
AECOPD	280 (16.9)	41 (9.9)	62 (15.0)	73 (17.7)	104 (25.2)	<0.001	
Smoke	498 (30.1)	143 (34.5)	121 (29.3)	115 (27.8)	119 (28.8)	0.149	
Laboratory events							
WBC, 10 ⁹ /L	10.40 [7.50, 14.30]	7.60 [5.40, 10.60]	9.70 [7.40, 12.60]	11.10 [8.40, 14.20]	14.40 [10.60, 19.40]	<0.001	
RBC, 10 ¹² /L	3.72 [3.15, 4.24]	3.62 [2.92, 4.18]	3.82 [3.23, 4.33]	3.73 [3.21, 4.23]	3.74 [3.16, 4.23]	0.003	
Hemoglobin, g/dl	11.00 [9.30, 12.60]	10.70 [8.80, 12.40]	11.30 [9.60, 12.70]	11.10 [9.40, 12.80]	10.80 [9.30, 12.30]	0.008	
Platelets, 10 ⁹ /L	196.00 [144.00, 256.00]	143.50 [98.00, 192.00]	186.00 [145.00, 240.00]	213.00 [168.00, 259.00]	252.00 [189.00, 318.00]	< 0.001	
RDW.%	14.50 [13.40, 16.10]	14.50 [13.30, 15.90]	14.40 [13.30, 15.80]	14.40 [13.40, 16.00]	14.80 [13.70, 17.00]	<0.001	
Neutrophils, 10 ⁹ /L	8.31 [5.41, 11.95]	4.36 [2.71, 6.43]	7.33 [5.48, 9.70]	9.30 [7.12, 12.63]	13.26 [10.32, 17.69]	< 0.001	
Lymphocytes, 10 ⁹ /L	1.18 [0.70, 1.86]	1.79 [1.14, 2.60]	1.48 [1.05, 2.05]	1.10 [0.76, 1.57]	0.63 [0.38, 0.93]	< 0.001	
Albumin, g/dL	3.30 [2.80, 3.70]	3.40 [2.90, 3.80]	3.40 [3.00, 3.75]	3.20 [2.80, 3.70]	3.10 [2.60, 3.52]	< 0.001	
Sodium, mEq/L	139.00 [136.00, 141.00]	139.00 [137.00, 141.75]	139.00 [136.00, 141.00]	138.00 [135.00, 141.00]	138.00 [135.00, 141.00]	0.001	
Potassium, mEg/L	4.10 [3.80, 4.60]	4.00 [3.70, 4.47]	4.20 [3.80, 4.60]	4.10 [3.80, 4.50]	4.30 [3.80, 4.70]	< 0.001	
Phosphate, mEq/L	3.60 [3.00, 4.27]	3.50 [2.90, 4.10]	3.50 [2.98, 4.20]	3.60 [3.00, 4.30]	3.70 [3.10, 4.47]	0.007	
Chloride, mEq/L	102.00 [98.00, 105.00]	103.00 [100.00, 107.00]	102.00 [98.00, 105.00]	102.00 [98.00, 105.00]	101.00 [96.00, 104.00]	<0.001	
Scr, mg/dl	1.00 [0.70, 1.40]	0.90 [0.70, 1.30]	0.90 [0.70, 1.20]	1.00 [0.70, 1.30]	1.00 [0.70, 1.50]	0.132	
BUN, mg/dl	19.00 [14.00, 30.00]	18.00 [13.00, 27.00]	18.00 [14.00, 27.00]	20.00 [14.00, 30.00]	23.00 [15.00, 36.00]	<0.001	
CRP, mg/L	58.40 [14.40, 117.20]	38.30 [6.90, 97.30]	73.80 [25.35, 116.85]	64.30 [12.17, 117.33]	79.00 [32.65, 145.05]	0.106	
Triglycerides, mg/dL	133.00 [96.50, 189.50]	138.00 [99.00, 192.00]	125.50 [98.00, 191.00]	115.00 [87.00, 175.00]	139.00 [107.00, 194.00]	0.116	
Glucose, mg/dl	119.50 [98.00, 158.00]	109.00 [93.00, 139.00]	118.00 [98.00, 153.00]	120.00 [100.00, 155.00]	134.00 [103.00, 174.00]	<0.001	
nt probnp	2551.00 [913.00, 7142.00]	1930.50 [478.00, 5230.50]	2006.50 [912.25, 6486.25]	3100.00 [1481.75, 7279.25]	2892.00 [932.50, 7972.00]	0.164	
PH	7.37 [7.31, 7.42]	7.38 [7.33, 7.42]	7.38 [7.32, 7.42]	7.38 [7.30, 7.42]	7.35 [7.28, 7.41]	0.006	
PaO ₂	88.50 [54.00, 231.75]	150.50 [64.00, 317.50]	98.00 [56.00, 288.00]	96.00 [59.00, 234.00]	73.00 [46.75, 127.25]	<0.001	
PaCO ₂	44.00 [38.00, 53.00]	43.00 [37.00, 49.00]	44.00 [39.00, 51.00]	44.00 [38.00, 54.00]	46.00 [39.00, 55.25]	0.004	
Tidal volume, mL	451.00 [397.00, 502.00]	454.00 [401.00, 510.00]	451.00 [404.75, 498.25]	450.00 [390.75, 493.00]	446.50 [387.00, 517.50]	0.537	
Vital capacity, L	1.46 [0.76, 618.75]	374.77 [187.66, 561.88]	700.00 [700.00, 700.00]	1.06 [0.50, 94.84]	1.46 [1.27, 450.73]	0.605	
Therapies, n (%)			,			0.005	
Antibiotic	1357 (82.1)	306 (73.9)	336 (81.4)	355 (86.0)	360 (87.2)	<0.001	
Bronchodilator	1343 (81.2)	308 (74.4)	347 (84.0)	337 (81.6)	351 (85.0)	<0.001	
Dionenodilator	1343 (01.2)	ד.די) סינ	ט.דט) זדנ	337 (01.0)	551 (0.0)	-0.001	

464

Dovepress

Glucocorticoids
Albumin
Vasopressor
Oxygen
Mechanical ventilation
Invasive
NonInvasive
SupplementalOxygen
Tracheostomy
CRRT
Scores
APSIII
SAPSII
OASIS
SOFA
Events
RF, n (%)

Glucocorticoids	831 (50.3)	177 (42.8)	209 (50.6)	213 (51.6)	232 (56.2)	0.001
Albumin	362 (21.9)	101 (24.4)	121 (29.3)	84 (20.3)	56 (13.6)	<0.001
Vasopressor	434 (26.3)	70 (16.9)	99 (24.0)	110 (26.6)	155 (37.5)	<0.001
Oxygen	953 (57.7)	203 (49.0)	246 (59.6)	233 (56.4)	271 (65.6)	<0.001
Mechanical ventilation	998 (60.4)	215 (51.9)	252 (61.0)	247 (59.8)	284 (68.8)	<0.001
Invasive	548 (33.2)	114 (27.5)	141 (34.1)	140 (33.9)	153 (37.0)	0.029
NonInvasive	121 (7.3)	14 (3.4)	34 (8.2)	32 (7.7)	41 (9.9)	0.003
SupplementalOxygen	880 (53.2)	192 (46.4)	231 (55.9)	210 (50.8)	247 (59.8)	<0.001
Tracheostomy	40 (2.4)	6 (1.4)	10 (2.4)	(2.7)	13 (3.1)	0.400
CRRT	77 (4.7)	16 (3.9)	19 (4.6)	14 (3.4)	28 (6.8)	0.100
Scores						
APSIII	43.00 [32.00, 56.00]	38.00 [29.00, 55.00]	42.00 [29.25, 53.75]	45.00 [32.00, 55.50]	45.50 [36.00, 60.00]	<0.001
SAPSII	37.00 [30.00, 47.00]	36.00 [29.00, 44.00]	37.00 [29.00, 44.75]	37.00 [30.00, 47.00]	39.00 [32.00, 50.25]	0.001
OASIS	33.00 [26.00, 38.00]	31.00 [26.50, 37.00]	32.00 [26.00, 37.00]	33.00 [27.00, 39.00]	34.00 [26.00, 40.00]	0.010
SOFA	5.00 [3.00, 8.00]	5.00 [3.00, 8.00]	5.00 [3.00, 8.00]	4.00 [2.00, 7.00]	5.00 [3.00, 8.00]	0.004
Events						
RF, n (%)	697 (42.2)	117 (28.3)	160 (38.7)	176 (42.6)	244 (59.1)	<0.001
Hypercapnic RF, n (%)	427 (25.8)	68 (16.4)	97 (23.5)	112 (27.1)	150 (36.3)	<0.001
Hospital death, n (%)	169 (10.2)	25 (6.0)	30 (7.3)	48 (11.6)	66 (16.0)	<0.001
ICU death, n (%)	130 (7.9)	19 (4.6)	26 (6.3)	33 (8.0)	52 (12.6)	<0.001
Follow-up death, n (%)	637 (38.5)	137 (33.1)	137 (33.2)	162 (39.2)	201 (48.7)	<0.001
LOS Hospital, days	8.00 [5.00, 15.00]	7.00 [4.00, 12.00]	8.00 [5.00, 15.00]	9.00 [5.00, 15.00]	9.00 [5.00, 16.00]	<0.001
LOS ICU, days	1.49 [0.00, 4.76]	1.05 [0.00, 3.05]	1.36 [0.00, 4.35]	1.68 [0.00, 5.01]	2.45 [0.00, 6.23]	<0.001
RF-time ^a , days	5.00 [1.00, 9.00]	5.00 [2.00, 8.00]	5.00 [2.00, 9.00]	5.00 [1.00, 10.00]	3.00 [1.00, 8.00]	<0.001
Hospital-time ^b , days	8.00 [5.00, 15.00]	7.00 [4.00, 12.00]	8.00 [5.00, 15.00]	9.00 [5.00, 15.00]	9.00 [5.00, 16.00]	<0.001
Longtime ^c , days	29.00 [8.00, 187.00]	32.00 [7.00, 227.50]	25.00 [7.00, 190.00]	29.00 [9.00, 181.00]	29.00 [9.00, 173.00]	0.811
NonInvasive SupplementalOxygen Tracheostomy CRRT Scores APSIII SAPSII OASIS SOFA Events RF, n (%) Hypercapnic RF, n (%) Hospital death, n (%) ICU death, n (%) ICU death, n (%) ICU death, n (%) Eollow-up death, n (%) LOS Hospital, days LOS ICU, days RF-time ^a , days	121 (7.3) 880 (53.2) 40 (2.4) 77 (4.7) 43.00 [32.00, 56.00] 37.00 [30.00, 47.00] 33.00 [26.00, 38.00] 5.00 [3.00, 8.00] 697 (42.2) 427 (25.8) 169 (10.2) 130 (7.9) 637 (38.5) 8.00 [5.00, 15.00] 1.49 [0.00, 4.76] 5.00 [1.00, 9.00] 8.00 [5.00, 15.00]	14 (3.4) 192 (46.4) 6 (1.4) 16 (3.9) 38.00 [29.00, 55.00] 36.00 [29.00, 44.00] 31.00 [26.50, 37.00] 5.00 [3.00, 8.00] 117 (28.3) 68 (16.4) 25 (6.0) 19 (4.6) 137 (33.1) 7.00 [4.00, 12.00] 1.05 [0.00, 3.05] 5.00 [2.00, 8.00] 7.00 [4.00, 12.00]	34 (8.2) 231 (55.9) 10 (2.4) 19 (4.6) 42.00 [29.25, 53.75] 37.00 [29.00, 44.75] 32.00 [26.00, 37.00] 5.00 [3.00, 8.00] 160 (38.7) 97 (23.5) 30 (7.3) 26 (6.3) 137 (33.2) 8.00 [5.00, 15.00] 1.36 [0.00, 4.35] 5.00 [2.00, 9.00] 8.00 [5.00, 15.00]	32 (7.7) 210 (50.8) 11 (2.7) 14 (3.4) 45.00 [32.00, 55.50] 37.00 [30.00, 47.00] 33.00 [27.00, 39.00] 4.00 [2.00, 7.00] 176 (42.6) 112 (27.1) 48 (11.6) 33 (8.0) 162 (39.2) 9.00 [5.00, 15.00] 1.68 [0.00, 5.01] 5.00 [1.00, 10.00] 9.00 [5.00, 15.00]	41 (9.9) 247 (59.8) 13 (3.1) 28 (6.8) 45.50 [36.00, 60.00] 39.00 [32.00, 50.25] 34.00 [26.00, 40.00] 5.00 [3.00, 8.00] 244 (59.1) 150 (36.3) 66 (16.0) 52 (12.6) 201 (48.7) 9.00 [5.00, 16.00] 2.45 [0.00, 6.23] 3.00 [1.00, 8.00] 9.00 [5.00, 16.00]	0.003 <0.001 0.400 0.100 <0.001 0.010 0.004 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001

Notes: ^aFollow-up time for respiratory failure; ^bFollow-up time for Hospital death; ^cFollow-up time for Follow-up death.

Abbreviations: SII, Systemic immune inflammatory index; N, Number; Q, Quartile; HR, Heart rate; RR, Respiratory rate; MBP, Mean blood pressure; SpO2, Saturation of peripheral oxygen; BMI, Body mass index; DM, Diabetes mellitus; HF, Heart failure; CHD, Coronary heart disease; AMI, Acute myocardial infarction; AF, Atrial fibrillation; IHD, Ischemic heart disease; CKD, Chronic kidney disease; AECOPD, Acute exacerbations of chronic obstructive pulmonary disease; WBC, White blood cell; RBC, Red blood cell; RDW, Red cell distribution width; Scr, Serum creatinine; BUN, Blood urea nitrogen; CRP, C-reactive protein; CRRT, Continuous renal replacement therapy; APSIII Acute physiology score III; SAPSII, Simplified acute physiological score II; OASIS, Oxford acute severity of illness; SOFA, Sequential organ failure assessment; ICU, Intensive care unit; RF, Respiratory failure; LOS length of stay.

(33.1% vs 33.2% vs 39.2% vs 48.7%, P<0.001) were elevated progressively. PSM analysis was performed with median SII as the cutoff value, and it was observed that the baseline features of the two groups were basically comparable after matching (<u>Table S1</u> in the Supporting Information). Significant differences were found in preliminary analysis of outcome indicators (<u>Table S2</u> in the Supporting Information).

Association Between SII and Outcomes

Cox proportional-hazards analysis unveiled (Table 2) that SII was significantly correlated with the incidence of RF [Model 1: HR, 1.31 (1.23–1.39), P < 0.001; Model 2: 1.30 (1.22–1.38), P < 0.001; Model 3: 1.19 (1.12–1.28), P<0.001] and the incidence of HRF [Model 1: HR, 1.29 (1.19–1.40), P < 0.001; Model 2: 1.29 (1.19–1.40), P < 0.001; Model 3: 1.16 (1.06–1.26), P<0.001]. In addition, compared with low SII (Q1), high SII (Q4) was linked to a higher incidence of RF [RF: Model 1: HR, 2.69 (2.15–3.35), P < 0.001; Model 2: 2.63 (2.11–3.29), P < 0.001; Model 3: 2.02 (1.59–2.57), P < 0.001]; HRF: Model 1: HR, 2.37 (1.78–3.15), P < 0.001; Model 2: 2.39 (1.79–3.20), P < 0.001; Model 3: 1.59 (1.17–2.15), P=0.003)].

Besides, SII was also significantly correlated with in-hospital mortality [Model 1: HR, 1.24 (1.09–1.41), P < 0.001; Model 2: 1.21 (1.06–1.37), P = 0.004; Model 3: 1.22 (1.07–1.39), P=0.003] and long-term follow-up mortality [Model 1: HR, 1.17 (1.09–1.25), P < 0.001; Model 2: 1.13 (1.06–1.21), P < 0.001; Model 3: 1.12 (1.05–1.19), P < 0.001].

Categories	Events (%)	Model I		Model 2		Model 3	
		HR (95% Cls)	p value	HR (95% Cls)	p value	HR (95% Cls)	p value
Respiratory failure							
Continuous variable per 1 unit (logSII)		1.31 (1.23–1.39)		1.30 (1.22–1.38)		1.19 (1.12–1.28)	
Quartile ^a	697 (42.2)		<0.001		<0.001		<0.001
QI (N=414)	117 (28.3)	Reference		Reference		Reference	
Q2 (N=413)	160 (38.7)	1.49 (1.17–1.89)	0.001	1.47 (1.15–1.86)	0.0018	1.41 (1.10–1.82)	0.008
Q3 (N=413)	176 (42.6)	1.58 (1.25–2.00)	<0.001	1.56 (1.23–1.97)	<0.001	1.45 (1.13–1.85)	0.003
Q4 (N=413)	244 (59.1)	2.69 (2.15–3.35)	<0.001	2.63 (2.11–3.29)	<0.001	2.02 (1.59–2.57)	<0.001
Hypercapnic respiratory failure							
Continuous variable per 1 unit (logSII)		1.29 (1.19–1.40)		1.29 (1.19–1.40)		1.16 (1.06–1.26)	
Quartile	427 (25.8)		<0.001		<0.001		<0.001
QI (N=414)	68 (16.4)	Reference		Reference		Reference	
Q2 (N=413)	97 (23.5)	1.44 (1.05–1.96)	0.022	1.45 (1.06–1.98)	0.0198	1.20 (0.87–1.66)	0.268
Q3 (N=413)	112 (27.1)	1.64 (1.21–2.22)	0.001	1.65 (1.22–2.24)	0.0012	1.39 (1.02–1.91)	0.040
Q4 (N=413)	150 (36.3)	2.37 (1.78–3.15)	<0.001	2.39 (1.79–3.20)	<0.001	1.59 (1.17–2.15)	0.003
In-hospital mortality							
Continuous variable per 1 unit (logSII)		1.24 (1.09–1.41)		1.21 (1.06–1.37)		1.22 (1.07–1.39)	
Quartile	169 (10.2)		<0.001		0.004		0.003
QI (N=414)	25 (6.0)	Reference		Reference		Reference	
Q2 (N=413)	30 (7.3)	1.10 (0.65–1.88)	0.7154	1.03 (0.60–1.75)	0.920	1.23 (0.69–2.19)	0.484
Q3 (N=413)	48 (11.6)	1.74 (1.07–2.83)	0.0248	1.60 (0.98–2.60)	0.060	2.26 (1.31–3.87)	0.003
Q4 (N=413)	66 (16.0)	2.20 (1.39–3.49)	<0.001	1.98 (1.25–3.16)	0.004	2.01 (1.21–3.36)	0.007
Long-term follow-up death							
Continuous variable per 1 unit (logSII)		1.17 (1.09–1.25)		1.13 (1.06–1.21)		1.12 (1.05–1.19)	
Quartile	637 (38.5)		<0.001		<0.001		<0.001
QI (N=414)	137 (33.1)	Reference		Reference		Reference	
Q2 (N=413)	137 (33.2)	1.13 (0.89–1.43)	0.323	1.03 (0.81–1.31)	0.792	1.04 (0.81–1.33)	0.773
Q3 (N=413)	162 (39.2)	1.26 (1.00–1.58)	0.047	1.16 (0.92–1.45)	0.218	1.27 (0.99–1.62)	0.056
Q4 (N=413)	201 (48.7)	1.66 (1.33–2.06)	<0.001	1.47 (1.18–1.84)	<0.001	1.32 (1.04–1.67)	0.022

Table 2 Cox Regression	Analysis for SII with	Respiratory Failure and	All-Cause Mortality
------------------------	-----------------------	-------------------------	---------------------

Notes: Model I: unadjusted. Model 2: adjusted for age, sex. Model 3: adjusted for age, sex, asthma, acute myocardial infarction, atrial fibrillation, cerebrovascular disease, chronic kidney disease, hypertension, heart failure, liver disease, pneumonia, sepsis, acute exacerbations of chronic obstructive pulmonary disease, smoke, bronchodilator, glucose, mechanical ventilation, albumin, red cell distribution width, triglycerides, c-reactive protein, tidal volume, vital capacity, acute physiology score III, sequential organ failure assessment, hemoglobin. aSII index: Q1 (≥634.51), Q2 (634.51<SII≤1302.17), Q3 (1302.17<SII≤2821.88), Q4 (>2821.88). Abbreviations: HR, hazard ratio; CI, confidence interval; SII, Systemic immune inflammatory index.

RCS analysis suggested a nonlinear correlation between SII and RF in Model 1 and Model 2 (P<0.001) (Figure 2A and B). In the RF Model 3 and HRF Model 1–3, the nonlinear relationship was not significant (P>0.05) (Figure 2C-F). Elevated SII (logSII>7.19) was linked to an elevated risk of RF in COPD patients. In addition, we also observed similar trends in in-hospital mortality and long-term follow-up mortality (Figure S1).

Incidence of All-Cause Mortality Among Different Groups

The Kaplan-Meier survival curve for intergroup all-cause mortality is shown in Figure 3. There were significant differences in the in-hospital mortality (Q1: 6.0% vs Q2: 7.3 vs Q3: 11.6 vs Q4: 16.0%, log-rank, P<0.001, Figure 3A) and long-term follow-up all-cause mortality (Q1: 33.1% vs Q2: 33.2 vs Q3: 39.2 vs Q4: 48.7%, log-rank, P < 0.001, Figure 3B) of each group. The association between increased mortality and higher SII disappeared after 21 days, with no statistical differences between groups (log-rank, P=0.097, Figure 3C). Landmark analysis showed that during the 21-day short-term follow-up period, individuals with higher SII had a higher all-cause mortality rate compared to those with lower SII. (Q1: 6.0% vs Q2: 7.3 vs Q3: 11.6 vs Q4: 16.0%, log-rank, P<0.001, Figure 3D). Besides, we also found that, with the increase of SII, the all-cause mortality of patients with RF did not show significant differences between different SII groups (Figure S2).

Subgroup Analysis

Subgroup analysis was executed to delve further into the link between SII and the incidence of RF. In the adjusted Model 3, the results unveiled that increased SII was closely related to an elevated risk of RF in COPD patients in most subgroups (Figure 4). The trends of the risk of RF in most subgroups were similar. In the subgroup analysis of RF, except for the obvious interaction observed in cancer (P<0.001), pneumonia (P = 0.001), sepsis (P = 0.005), and BMI (P = 0.019), the majority of stratification factors did not considerably affect the correlation between SII and RF (Figure 4A). However, no significant interaction factors were found in the HRF subgroup (Figure 4B).




Figure 2 Restricted cubic spline analysis of SII with respiratory failure incidence. (A-C) Restricted cubic spline for respiratory failure. (D-F) Restricted cubic spline for hypercapnic respiratory failure. Heavy central lines represent the estimated adjusted hazard ratios; with shaded ribbons denoting 95% confidence intervals. logSII index 7.19 was selected as the reference level represented by the vertical dotted lines. The horizontal dotted lines represent the hazard ratio of 1.0. Abbreviations: HR, hazard ratio; CI, confidence interval; SII, Systemic immune inflammatory index.




Figure 3 Kaplan–Meier survival analysis curves for all-cause mortality. SII index: QI (SII \geq 634.51), Q2 (634.51<SII \leq 1302.17), Q3 (1302.17<SII \leq 2821.88), Q4 (SII \geq 2821.88). Kaplan–Meier curves showing cumulative probability of in-hospital mortality (**A**), long-term follow-up death (**B**), landmark analysis from 21 days to 10 years (**C**), and Kaplan–Meier survival analysis curves for all-cause mortality according to groups at 21 days (**D**).

Discussion

This study is the pioneer, to our knowledge, in probing into the link between SII and the risk of RF and death in COPD patients. In this study, 1653 critically ill patients with COPD from the MIMIC-IV database were included, and the large sample size increased the reliability of the results. According to the findings, a higher SII was linked to a higher risk of RF and death as well as a longer hospital stay. Accordingly, SII may be a useful novel predictor of the prognosis of COPD patients. In addition, this correlation is still significant in PSM analysis, variable adjustment, and subgroup analysis. This enhances the validity of SII as a prognostic marker. Our findings are clinically significant in that SII may aid in early identifying high-risk COPD patients, carrying out early intervention, and promoting risk stratification management.

Subgroups Adjusted HR(95%CI) P value P for interaction А 1.37 (1.24, 1.52) < 0.001 Sex (female) 0.501 < 0.001 Sex (male) 1.28 (1.18, 1.39) 1.44 (1.33, 1.55) <0.001 <0.001 Cancer -Cancer + 1.08 (0.97, 1.21) 0.171 CHD -1.29 (1.19, 1.39) <0.001 0.591 CHD + <0.001 1.34 (1.20, 1.49) DM -1.32 (1.22, 1.43) < 0.001 0.669 DM + < 0.001 1.28 (1.15, 1.43) Dyslipidemia -1.24 (1.14, 1.34) < 0.001 0.071 < 0.001 Dvslipidemia + 1.40 (1.26, 1.55) HF -1.34 (1.22, 1.47) < 0.001 0.325 HF + 1.26 (1.15, 1.38) < 0.001 Hypertension -1.25 (1.11, 1.40) < 0.001 0.337 Hypertension + 1.33 (1.24, 1.44) < 0.001 0.960 IHD -1.31 (1.20, 1.43) < 0.001 IHD + 1.31 (1.19, 1.45) < 0.001 < 0.001 0.255 Liver disease -1.33 (1.24, 1.43) Liver disease + 1.44 (1.25, 1.66) <0.001 1.35 (1.25, 1.47) < 0.001 0.001 Pneumonia -Pneumonia + 1.10 (1.00, 1.21) 0.048 <0.001 0.005 Sepsis -1.30 (1.20, 1.41) Sepsis + 1.08 (0.97, 1.20) 0.160 AECOPD -< 0.001 1.31 (1.21, 1.41) 0.052 AECOPD + 1.15 (1.02, 1.29) 0.021 1.29 (1.20, 1.40) < 0.001 0.635 Smoke -Smoke + 1.35 (1.21, 1.52) < 0.001 BMI<=30kg/m2 1.21 (1.09, 1.34) < 0.001 0.019 BMI>30kg/m2 1.44 (1.22, 1.70) < 0.001 Age<=65 years 1.22 (1.09, 1.36) 0.001 0.144 Age>65 years 1.35 (1.25, 1.46) < 0.001 P for interaction Subgroups Adjusted HR(95%CI) P value В Sex (female) 1.32 (1.17, 1.50) <0.001 0.573 Sex (male) 1.26 (1.13, 1.41) < 0.001 Cancer -1.36 (1.23, 1.49) < 0.001 0.131 Cancer + 1.18 (1.01, 1.39) 0.036 CHD -1.32 (1.20, 1.46) <0.001 0.322 CHD+ 1.21 (1.04, 1.41) 0.014 DM -1.32 (1.19, 1.46) < 0.001 0.634 DM+ 1.27 (1.11, 1.46) 0.001 < 0.001 0.080 Dyslipidemia -1.21 (1.09, 1.34) Dyslipidemia + 1.41 (1.23, 1.61) <0.001 HF -<0.001 0.069 1.38 (1.22, 1.55) HF + 1.18 (1.05, 1.33) 0.004 0.010 0.346 Hypertension -1.22 (1.05, 1.41) Hypertension + 1.32 (1.20, 1.46) <0.001 IHD -1.32 (1.19, 1.47) <0.001 0.534 IHD + 1.25 (1.10, 1.43) 0.001 Liver disease -1.33 (1.22, 1.46) < 0.001 0.482 Liver disease + 1.23 (1.02, 1.48) 0.027 Pneumonia -1.31 (1.17, 1.45) <0.001 0.094 Pneumonia + 1.14 (1.02, 1.28) 0.023 Sepsis -1.21 (1.09, 1.33) <0.001 0.628 Sepsis + 1.25 (1.08, 1.44) 0.002 AECOPD -1.28 (1.16, 1.42) <0.001 0.221 AECOPD + 0.038 1.15 (1.01, 1.32) Smoke -1.27 (1.15, 1.40) <0.001 0.532 Smoke + 1.35 (1.16, 1.56) <0.001 BMI<=30kg/m2 1.25 (1.09, 1.43) 0.001 0.411 0.008 BMI>30kg/m2 1.31 (1.07, 1.59) Age<=65 years 1.17 (1.02, 1.34) 0.028 0.058 <0.001 Age>65 years 1.38 (1.24, 1.52)

Figure 4 Subgroup analysis of the relationship between SII and respiratory failure.(A) Subgroup analysis for respiratory failure. (B)Subgroup analysis for hypercapnic respiratory failure.

Abbreviations: HR, hazard ratio; CI, confidence interval; SII, Systemic immune inflammatory index; BMI, body mass index; DM, diabetes mellitus.

Nevertheless, the mechanism of SII linked to the poor prognosis of COPD is still unclear. There is a characteristic inflammatory pattern in COPD patients, that is, there is an increased number of neutrophils in the airway tract and macrophages, T lymphocytes, and B lymphocytes.^{16,30,31} Numerous immune cells, like lymphocytes and neutrophils, participate in the inflammatory response.^{14,17,32} In recent years, it has been found that platelets are involved in the inflammatory response of sepsis and other serious infections, and serve as a main contributor to the occurrence and progression of COPD.¹⁵ When infection occurs, inflammation activates the coagulation pathway and initiates platelet activation. Then the activated platelets can secrete pro-inflammatory substances and chemokines, regulate the function of white blood cells, and then participate in and induce the inflammatory process.

SII combines the predictive ability of neutrophil, lymphocyte, and platelet count, allowing it to accurately and thoroughly reflect our body's inflammatory and immune condition. In some diseases, SII is a powerful prognostic indicator compared with the systemic inflammatory response biomarkers, encompassing neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte-lymphocyte ratio (MLR).^{33,34} Although inflammatory molecules, consisting of tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and procalcitonin, perform well in the prognosis evaluation of patients,¹⁹ they are unable to accurately express the inflammatory and immune state of our body, and the high detection cost also limits their clinical application. The SII index is obtained from blood tests, which are common-place for almost all hospitalized patients and are easily accessible in clinical practice. It is simple, fast, and cost-effective, and has broad application prospects, particularly, in underdeveloped areas.

Based on Cox proportional-hazards regression analysis, higher SII at admission amplifies the risk of RF and death, whether confounding factors are adjusted or not. Therefore, it is reasonable to conclude that SII is valuable and reliable in forecasting the prognosis of COPD patients. Through the Kaplan-Meier curve, we observed that patients with high SII had an elevated risk of mortality over time. Considerable differences were noted in the risk of death among the three groups. This significance was especially obvious in the early stage (within 21 days of admission). We suspected that the early inflammatory cytokine storm is more prominent, and a large number of inflammatory-related cytokines are increased and activated. This initial stage has a greater impact on the prognosis. SII is more valuable for forecasting short-term prognosis than for long-term prognosis.

There are also many previous studies on the predictive indicators of COPD patients.^{35–37} However, these studies often focus on mortality, and lack subgroup analysis on whether COPD patients have RF or RF types. Considering that once COPD patients are complicated with RF, it is often difficult to treat and results in high mortality. Therefore, in addition to mortality, RF is used as the primary outcome measure, which enriches the root cause analysis of this research. In addition, we also analyzed the mortality of patients with RF. The results showed that with the rise in SII, there was no significant difference in the risk of death among different groups in the COPD+RF population, possibly owing to the high-grade inflammation and high mortality of RF patients themselves. Therefore, in COPD patients, early identification of those with high risks of inflammation and RF is essential for the clinical treatment of COPD, thereby decreasing mortality and ameliorating prognosis.³⁸

In the description of baseline characteristics, our study is more detailed than other similar studies.^{36,37} We included smoking history, BMI, the use of glucocorticoids, bronchodilators, antibiotics, mechanical ventilation, and information about other diseases that may cause inflammation, such as pneumonia and sepsis. Our findings revealed that patients with higher SII are more susceptible to cancers, heart failure, AECOPD, pneumonia, and sepsis. Although cancer, pneumonia, sepsis, and BMI showed obvious connections with RF, this effect was not observed in the subgroup analysis of HRF. HRF is the most typical type of RF in COPD. Therefore, this seems to further prove the validity of SII as a prognostic indicator of COPD, especially in forecasting the risk of HRF. In addition, patients with higher SII were less prone to liver diseases and dyslipidemia. A previous study has shown that severe liver diseases may affect the coordinated response of the liver to infection.³⁹ Metabolic syndrome, including dyslipidemia, is closely related to systemic inflammation and cardiovascular risk.^{40,41} This seems to be inconsistent with our results, but no significant interaction between these two factors was found in subgroup analysis. The influence of liver diseases and blood lipids on inflammation needs to be further validated in future research.

Besides, the predictive power of SII for the prognosis of COPD+RF patients with cancer and sepsis is relatively weak. These conditions need to be considered when predicting the risk of RF in COPD patients. We hypothesized that these patients had obvious immune inflammatory reactions at the time of admission, which may affect the baseline white blood cell counts. When it comes to RF in COPD patients, pneumonia, sepsis, and cancers have to be considered. This is consistent with previous literature.^{42–44} Previous studies have also confirmed that the poor prognosis of these diseases is usually related to inflammation.^{27,42} However, we found that there were few patients in these subgroups. Therefore, these differences may be caused by small sample sizes.

Certainly, several limitations need to be considered. Firstly, since our study is single-center retrospective, the selection bias cannot be disregarded, limiting the generalizability of these results to other populations. Therefore, a large-scale multicenter prospective study is required in the future to further support our views. Secondly, due to the retroactive nature of the data collection, several significant variables might have been missed. Although we made adjustments for the confounding variables, our findings could still be affected by unidentified factors. Thirdly, Thirdly, changes throughout hospitalization were not taken into account when calculating SII; instead, just SII values at admission were used. Therefore, the ideal time period needs to be investigated. Fourthly, our research lacks information about other inflammatory markers, such as procalcitonin, IL-1, IL-6, and TNF- α , as well as blood culture and pathogenic bacteria. These may affect the baseline white blood cell counts. Ultimately, it is impossible to identify the likely mechanism underlying the link between high SII and a poor prognosis of COPD patients in this study. Consequently, additional research is warranted.

Conclusion

In conclusion, high SII may be closely correlated with a poor prognosis of critically ill COPD patients, such as a high risk of RF and all-cause mortality. Therefore, SII serves as a potential, cost-effective, and easily available biomarker for early risk assessment of this population. Nevertheless, larger prospective studies with long-term follow-up are desired to corroborate our conclusions.

Abbreviations

COPD, chronic obstructive pulmonary disease; SII, Systemic immune-inflammation index; MIMIC-IV, Medical Information Mart for Intensive Care IV; RF, Respiratory failure; HRF, hypercapnic Respiratory failure; SOFA, The sequential organ failure assessment; HF, Heart failure; SOFA, Sequential organ failure assessment; APSIII, Acute physiology score III; SAPSII, Simplified acute physiological score II; CHD, Coronary heart disease; AF, Atrial fibrillation; DM, Diabetes mellitus; CKD, Chronic kidney disease; AKI, Acute kidney injury; IQR, Interquartile range; PSM, Propensity score matching; RCS, Restricted cubic spline; BMI, Body mass index; RBC, Red blood cell; ICU, Intensive care unit; ICD-9, The ninth revision of the International Classification of Diseases; ICD-10, The tenth revision of the International Classification of Diseases; ICD-10, The tenth revision of the International classification of Diseases; NT-proBNP, N-terminal pro brain natriuretic peptide; AMI, Acute myocardial infarction; HR, Hazard ratio; CI, Confidence interval; N, Number; Q, Quartile; RR, Respiratory rate; MBP, Mean blood pressure; SpO2, Saturation of peripheral oxygen; IHD, Ischemic heart disease; WBC, White blood cell; RDW, Red cell distribution width; Scr, Serum creatinine; BUN, Blood urea nitrogen; CRP, C-reactive protein; CRRT, Continuous renal replacement therapy; OASIS, Oxford acute severity of illness; LOS, length of stay; MIT, the Massachusetts Institute of Technology; BIDMC, the Beth Israel Deaconess Medical Center; PaO2, arterial oxygen partial pressure; FiO2, fractions of inspired oxygen; CO2, carbon dioxide.

Data Sharing Statement

Relevant data were retrospectively acquired from the Medical Information Mart for Intensive Care-IV (MIMIC-IV version 2.2) database (https://physionet.org/content/mimiciv/2.2/).

Ethics Approval and Informed Consent

This project was approved by the institutional review committee of MIT and BIDMC. All the protected private information of patients has been de-identified. Ethical approval for this study was obtained from the Medical Research Ethics Committee of The First Hospital of Jiaxing (No. 2023-LY-633).

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This study was supported by Scientific Technology Plan Program for Healthcare in Zhejiang Province (NO. 2021KY1100), Jiaxing Science and Technology Plan Project (NO. 2022AD30055), the Key Discipline of JiaxingGenral Practice Medicine Construction Project (No.2023-fc-002), Key Construction Disciplines of Provincial and Municipal Co construction of Zhejiang [NO.2023-SSGJ-002].

Disclosure

The authors declare that they have no conflicts of interest in this work.

References

- 1. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227-2242. doi:10.1016/s0140-6736(22)00470-6
- Wang Z, Locantore N, Haldar K, et al. Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: a Multicohort Longitudinal Analysis. Am J Respir Crit Care Med. 2021;203(12):1488–1502. doi:10.1164/ rccm.202009-34480C
- 3. Burney PG, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990-2010. Eur Respir J. 2015;45(5):1239–1247. doi:10.1183/09031936.00142414
- 4. Papadopoulos G, Vardavas CI, Limperi M, Linardis A, Georgoudis G, Behrakis P. Smoking cessation can improve quality of life among COPD patients: validation of the clinical COPD questionnaire into Greek. *BMC Pulm Med.* 2011;11:13. doi:10.1186/1471-2466-11-13
- 5. Scala R, Heunks L. Highlights in acute respiratory failure. Eur Respir Rev. 2018;27(147):180008. doi:10.1183/16000617.0008-2018
- 6. Khilnani GC, Banga A, Sharma SK. Predictors of mortality of patients with acute respiratory failure secondary to chronic obstructive pulmonary disease admitted to an intensive care unit: a one year study. BMC Pulm Med. 2004;4:12. doi:10.1186/1471-2466-4-12
- 7. Zhou L, Guan L, Wu W, et al. High-pressure versus low-pressure home non-invasive positive pressure ventilation with built-in software in patients with stable hypercapnic COPD: a pilot study. *Sci Rep.* 2017;7(1):16728. doi:10.1038/s41598-017-17142-2
- Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10(2):81–89. doi:10.1513/AnnalsATS.201208-043OC
- Bustamante-Fermosel A, De Miguel-Yanes JM, Duffort-Falcó M, Muñoz J. Mortality-related factors after hospitalization for acute exacerbation of chronic obstructive pulmonary disease: the burden of clinical features. Am J Emerg Med. 2007;25(5):515–522. doi:10.1016/j.ajem.2006.09.014
- 10. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax*. 2012;67(11):970–976. doi:10.1136/thoraxjnl-2012-202103
- 11. Chen CW, Chen YY, Lu CL, et al. Severe hypoalbuminemia is a strong independent risk factor for acute respiratory failure in COPD: a nationwide cohort study. Int J Chron Obstruct Pulmon Dis. 2015;10:1147–1154. doi:10.2147/copd.S85831
- 12. Halpin DM, Miravitlles M, Metzdorf N, Celli B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. *Int J Chron Obstruct Pulmon Dis.* 2017;12:2891–2908. doi:10.2147/copd.S139470
- 13. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35(1):71-86. doi:10.1016/j. ccm.2013.10.004
- 14. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. doi:10.1016/j.jaci.2016.05.011
- 15. Chen YR, Chen V, Hollander Z, et al. C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. *PLoS One*. 2017;12(3):e0174063. doi:10.1371/journal.pone.0174063
- Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378(9795):1015– 1026. doi:10.1016/s0140-6736(11)60988-4
- Yamaya M, Usami O, Nakayama S, et al. Malnutrition, Airflow Limitation and Severe Emphysema are Risks for Exacerbation of Chronic Obstructive Pulmonary Disease in Japanese Subjects: a Retrospective Single-Center Study. Int J Chron Obstruct Pulmon Dis. 2020;15:857–868. doi:10.2147/copd.S238457
- Zhao J, Feng J, Ma Q, Li C, Qiu F. Prognostic value of inflammation biomarkers for 30-day mortality in critically ill patients with stroke. Front Neurol. 2023;14:1110347. doi:10.3389/fneur.2023.1110347
- 19. Şahin F, Koşar AF, Aslan AF, Yiğitbaş B, Uslu B. Serum Biomarkers in Patients with Stable and Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Comparative Study. J Med Biochem. 2019;38(4):503-511. doi:10.2478/jomb-2018-0050
- 20. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res.* 2014;20(23):6212–6222. doi:10.1158/1078-0432.Ccr-14-0442
- 21. Wang BL, Tian L, Gao XH, et al. Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. *Clin Chem Lab Med.* 2016;54(12):1963–1969. doi:10.1515/cclm-2015-1191

- Tang Y, Zeng X, Feng Y, et al. Association of Systemic Immune-Inflammation Index With Short-Term Mortality of Congestive Heart Failure: a Retrospective Cohort Study. Front Cardiovasc Med. 2021;8:753133. doi:10.3389/fcvm.2021.753133
- 23. Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. *Eur J Clin Invest.* 2020;50(5):e13230. doi:10.1111/eci.13230
- 24. Wu S, Shi X, Zhou Q, Duan X, Zhang X, Guo H. The Association between Systemic Immune-Inflammation Index and All-Cause Mortality in Acute Ischemic Stroke Patients: analysis from the MIMIC-IV Database. *Emerg Med Int.* 2022;2022:4156489. doi:10.1155/2022/4156489
- Hu L, Yu J, Deng J, Zhou H, Yang F, Lu X. Development of nomogram to predict in-hospital death for patients with intracerebral hemorrhage: a retrospective cohort study. *Front Neurol.* 2022;13:968623. doi:10.3389/fneur.2022.968623
- 26. Jia L, Li C, Bi X, et al. Prognostic Value of Systemic Immune-Inflammation Index among Critically III Patients with Acute Kidney Injury: a Retrospective Cohort Study. J Clin Med. 2022;11(14):3978. doi:10.3390/jcm11143978
- 27. Jiang D, Bian T, Shen Y, Huang Z. Association between admission systemic immune-inflammation index and mortality in critically ill patients with sepsis: a retrospective cohort study based on MIMIC-IV database. *Clin Exp Med.* 2023;1–10. doi:10.1007/s10238-023-01029-w
- Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: a Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93(10):1488–1502. doi:10.1016/j.mayocp.2018.05.026
- Blazek K, van Zwieten A, Saglimbene V, Teixeira-Pinto A. A practical guide to multiple imputation of missing data in nephrology. *Kidney Int.* 2021;99(1):68–74. doi:10.1016/j.kint.2020.07.035
- Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350 (26):2645–2653. doi:10.1056/NEJMoa032158
- 31. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-192. doi:10.1038/nri2254
- 32. Pan QX, Su ZJ, Zhang JH, Wang CR, Ke SY. A comparison of the prognostic value of preoperative inflammation-based scores and TNM stage in patients with gastric cancer. Onco Targets Ther. 2015;8:1375–1385. doi:10.2147/ott.S82437
- Mirili C, Paydas S, Kapukaya TK, Yılmaz A. Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. *Biomarker Med.* 2019;13(18):1565–1575. doi:10.2217/bmm-2019-0303
- 34. Shoji F, Takeoka H, Kozuma Y, et al. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 2019;136:45–51. doi:10.1016/j.lungcan.2019.08.006
- 35. Zuo H, Xie X, Peng J, Wang L, Zhu R. Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Anal Cell Pathol. 2019;2019:5189165. doi:10.1155/2019/5189165
- 36. Fan L, Sun D, Yang J, et al. Association Between Serum Sodium and Long-Term Mortality in Critically III Patients with Comorbid Chronic Obstructive Pulmonary Disease: analysis from the MIMIC-IV Database. Int J Chron Obstruct Pulmon Dis. 2022;17:1143–1155. doi:10.2147/copd. S353741
- 37. Qiu Y, Wang Y, Shen N, et al. Association Between Red Blood Cell Distribution Width-Albumin Ratio and Hospital Mortality in Chronic Obstructive Pulmonary Disease Patients Admitted to the Intensive Care Unit: a Retrospective Study. Int J Chron Obstruct Pulmon Dis. 2022;17:1797–1809. doi:10.2147/copd.S371765
- 38. Zhou F, Xiong X, Li S, et al. Enhanced autophagic retrograde axonal transport by dynein intermediate chain upregulation improves Aβ clearance and cognitive function in APP/PS1 double transgenic mice. *Aging (Albany NY)*. 2020;12(12):12142–12159. doi:10.18632/aging.103382
- Bernsmeier C, van der Merwe S, Périanin A. Innate immune cells in cirrhosis. *J Hepatol.* 2020;73(1):186–201. doi:10.1016/j.jhep.2020.03.027
 Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. *Circulation.* 2005;111(11):1448–1454. doi:10.1161/01.Cir.0000158483.13093.9d
- Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. *Chest.* 2009;136(4):1039–1046. doi:10.1378/chest.09-0393
- 42. Afessa B, Morales IJ, Scanlon PD, Peters SG. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. *Crit Care Med.* 2002;30(7):1610–1615. doi:10.1097/00003246-200207000-00035
- Ucgun I, Metintas M, Moral H, Alatas F, Yildirim H, Erginel S. Predictors of hospital outcome and intubation in COPD patients admitted to the respiratory ICU for acute hypercapnic respiratory failure. *Respir Med.* 2006;100(1):66–74. doi:10.1016/j.rmed.2005.04.005
- 44. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):959–967. doi:10.1164/ajrccm.154.4.8887592

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

DovePress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www. dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal

🖬 🔰 in 🖪

473